Two phase 1 studies evaluated the safety and metabolic effects of eptinezumab (a calcitonin gene‐related peptide [CGRP] inhibitor) in non‐migraine overweight/obese patients (study 1) and non‐migraine patients with type 1 diabetes (T1D; study 2), given that CGRP has also been implicated in the regulation of insulin secretion. This evidence concerns the gene INS and migraine disorder.